Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HILLCLIMBER: High vs Moderate Intensity Statin in HIV with CHD
NCT02841774Phase 2Completed
- Start
- Nov 2016
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rosuvastatin in coronary heart disease (CHD) (2 arms). Primary endpoints: Mean Percent Change in Fasting LDL-cholesterol at 14 weeks and Treatment-emergent Adverse Events at 14 weeks. Started Nov 2016; status: completed.
02
Drugs
rosuvastatin
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT02841774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02841774.